Status:
COMPLETED
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Lead Sponsor:
Tranzyme, Inc.
Conditions:
Gastroparesis
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active dru...
Detailed Description
Considered subjects will be screened to determine eligibility for entry into the study. The Screening Visit must take place at least 14 days, but not more than 21 days, before the planned date of stud...
Eligibility Criteria
Inclusion
- 18 to 80 years of age, inclusive
- Type 1 or type 2 diabetes mellitus
- History of symptoms of gastroparesis for at least 3 months leading up to the Screening Visit
- Gastric half-emptying time \>82 minutes, demonstrated by the Gastric Emptying Breath Test performed at the Screening Visit OR documented delayed gastric emptying within the previous 24 months
- Mild to moderate severity of gastroparesis symptoms during the screening period
- Body Mass Index (BMI) \< 45.0 at the Screening Visit
- Glycosylated hemoglobin (HbA1c) level \< 11.0% at the Screening Visit
- Upper gastrointestinal obstruction ruled out by endoscopy or barium scan
- Concomitant medications must be stable for at least 2 weeks leading up to the Baseline Visit and must be maintained during the study.
- Females of child-bearing potential must have a negative serum pregnancy test and use (and agree to continue to use throughout the study) an acceptable form of contraception.
Exclusion
- Persistent daily vomiting
- Gastrectomy, bariatric surgery, fundoplication or vagotomy/pyloroplasty
- Has had or plans to have endoscopic pyloric injections of botulinum toxin within 6 months prior to the Screening Visit or during the study.
- NG, PEG or PEJ feeding tube within 2 weeks prior to the Screening Visit
- Required in-patient hospitalization for treatment of gastroparesis within 2 weeks prior to the Screening Visit
- Required parenteral nutrition for treatment of gastroparesis within 2 months prior to the Screening Visit
- Active gastric pacemaker within 3 months prior to the Screening Visit
- Participated in an investigational study within 30 days prior to the Screening Visit
- Chronic severe diarrhea
- Diabetic ketoacidosis that required inpatient hospitalization within 30 days prior to the Screening Visit
- History of any eating disorder within 2 years prior to the Screening Visit
- Chronic obstructive pulmonary disease (COPD) or chronic asthma
- Chronic smoker that is unable or unwilling to abstain from smoking during the two visits that the gastric emptying breath test will be performed
- History of risk factors for Torsades de Pointes
- Corrected QT interval calculated using Fredericia's formula \>= 500 msec, recorded and confirmed on any of the three ECG assessments performed during the screening period
- Bradycardia or hypotension assessed as clinically-significant by the investigator
- Requires treatment with concomitant medication that is a substrate of Cytochrome P450 isoenzyme 3A4 and known to have a clinically recognized risk for Torsades de Pointes
- History of acute myocardial infarction, unstable angina or a transient (cerebral) ischemic attack within 12 months prior to the Screening Visit
- History of severe depression, psychiatric disorder or cognitive impairment
- History of alcohol or drug abuse or dependency within 2 years prior to the Screening Visit
- Taking opiates for abdominal pain
- Known history of Hepatitis B or C or HIV infection
- Requires dialysis or elevated creatinine at the Screening Visit
- Abnormal liver function tests at the Screening Visit
- Uncontrolled hypo- or hyperthyroidism
- Adrenal insufficiency
- Active malignancy other than basal cell or squamous cell carcinoma of the skin
- Pregnant or breast-feeding
- Allergies to components of the breath test meal or severe lactose intolerance
- Any other medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT01452815
Start Date
September 1 2011
End Date
November 1 2012
Last Update
April 25 2013
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Tranzyme Investigational Site
Huntsville, Alabama, United States, 35801
2
Tranzyme Investigational Site
Tucson, Arizona, United States, 85710
3
Tranzyme Investigational Site
Jonesboro, Arkansas, United States, 72401
4
Tranzyme Investigational Site
Little Rock, Arkansas, United States, 72117